Clinical Trial

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
Protocol Amendment History 1 change
notable Trial sites expanded: 152 -> 155 locations 2026-07-14
Trial Details
NCT Number NCT06742996
Lead Sponsor BeOne Medicines
Conditions Mantle Cell Lymphoma, B Cell Lymphoma
Enrollment 300 participants
Start Date 2025-03-05
Primary Completion 2028-08-31 (estimated)
Study Completion 2032-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-22